New immune Tx achieves remission in B-cell malignancies

February 17, 2016

(HealthDay)—A new T-cell immunotherapy has led to sustained regression in many previously relapsing and treatment-resistant cases of acute lymphoblastic leukemia, non-Hodgkin's lymphoma, and chronic lymphocytic leukemia, according to research presented at the annual meeting of the American Association for the Advancement of Science (AAAS), held from Feb. 11 to 15 in Washington, D.C.

The therapy involves removing T cells from patients, using gene transfer to introduce highly potent receptors that target the cancer (chimeric antigen receptors), and then placing them back in the body. The altered T cells then seek and destroy cancer. In a clinical trial, symptoms vanished in 94 percent of patients who received the treatment. The response rate was more than 80 percent in patients with other B-cell malignancies, and half achieved total remission, CNBC reported.

The results are unprecedented, according to researcher Stanley Riddell, M.D., an immunotherapy researcher and oncologist at the Fred Hutchinson Cancer Research Center in Seattle. "In the laboratory and in clinical trials, we are seeing dramatic responses in patients with tumors," he said at the AAAS meeting. "Unlike a chemotherapy drug which destroys cancer cells that are growing, you put in a living therapy that engages the in hand to hand combat." In who receive the therapy, "the bone marrow just goes from being full of leukemia to being in remission, and very large tumors simply melt away," Riddell said on his company website, CNBC reported.

The results are revolutionary, according to Chiara Bonini, M.D., of the San Raffaele Scientific Institute in Milan. "The last time (I saw) a change in remission rates like this must have been in 2000," she said during the presentation. "T are a living drug, and in particular they have the potential to persist in our body for our whole lives."

The research is funded by Juno Therapeutics, which was initially formed on technology from researchers at Fred Hutchinson, Memorial Sloan-Kettering Cancer Center, and Seattle Children's Research Institute to commercialize promising immunotherapies.

Explore further: Stan Riddell, Fred Hutch cancer immunotherapy innovator, to present at AAAS Annual Meeting

More information: Abstract

Related Stories

Stan Riddell, Fred Hutch cancer immunotherapy innovator, to present at AAAS Annual Meeting

February 14, 2016
Dr. Stanley Riddell, an immunotherapy researcher and oncologist at Seattle's Fred Hutchinson Cancer Research Center, on Feb. 14 will present an update on new adoptive T-cell strategies for cancer at the annual meeting of ...

Progress in fighting cancer and infections with T cell therapy

February 14, 2016
The quest to bring immunotherapy into widespread clinical use against cancer and infectious diseases has made great strides in recent years. For example, clinical trials of adoptive T cell therapy are yielding highly promising ...

US regulators fast-track novel leukemia therapy

July 7, 2014
US regulators on Monday put an experimental immunotherapy agent on the fast track to market approval, after 89 percent of leukemia patients in early trials saw their cancers disappear.

Study shows new kind of targeted drug has promise for leukemia patients

December 7, 2014
A new type of cancer therapy that targets an oncometabolite produced dramatic results in patients with advanced leukemia in an early-phase clinical trial. The study, led by Eytan M. Stein, MD, a medical oncologist at Memorial ...

First-in-class drug ONC201 shows potential for some blood cancers

February 16, 2016
ONC201, an anti-cancer drug that triggers cell death in various tumor types, may have clinical potential for some blood cancers including mantel cell lymphoma (MCL) and acute myeloid leukemia (AML), according to a recent ...

High response rates, long-term remissions in Penn trials of personalized cell therapy

December 7, 2015
Ninety-three percent of pediatric patients (55 of 59) with relapsed/refractory acute lymphoblastic leukemia (ALL) went into remission after receiving an investigational therapy made from their own immune cells, with continuous ...

Recommended for you

Function of neutrophils during tumor progression unraveled

October 15, 2018
Researchers at The Wistar Institute have characterized the function of neutrophils, a type of white blood cells, during early stages of tumor progression, showing that they migrate from the bone marrow to distant sites and ...

Delving where few others have gone, leukemia researchers open new path

October 15, 2018
A Wilmot Cancer Institute study uncovers how a single gene could be at fault in acute myeloid leukemia (AML), one of the deadliest cancers. The breakthrough gives researchers renewed hope that a gene-targeted therapy could ...

3-D mammography detected 34% more breast cancers in screening

October 15, 2018
In traditional mammography screening, all breast tissue is captured in a single image. Breast tomosynthesis, on the other hand, is three-dimensional and works according to the same principle as what is known as tomography. ...

More clues revealed in link between normal breast changes and invasive breast cancer

October 15, 2018
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process—changes in mammary glands to accommodate breastfeeding—uses a molecular process believed ...

Cancer stem cells use 'normal' genes in abnormal ways

October 12, 2018
CDK1 is a "normal" protein—its presence drives cells through the cycle of replication. And MHC Class I molecules are "normal" as well—they present bits of proteins on the surfaces of cells for examination by the immune ...

Obesity linked to increased risk of early-onset colorectal cancer

October 12, 2018
Women who are overweight or obese have up to twice the risk of developing colorectal cancer before age 50 as women who have what is considered a normal body mass index (BMI), according to new research led by Washington University ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.